“…In 2001, the Assessment of Spondyloarthritis international Society (ASAS) developed a preliminary definition of clinical remission-ASAS partial remission (ASAS PR), which includes assessment of 4 domains: patient global, spinal pain, physical function, and "inflammation" (a proxy for true inflammation, based on morning stiffness) 5 . In clinical trials, 12-15% 5,6 of patients with ankylosing spondylitis (AS) receiving nonsteroidal antiinflammatory drugs (NSAID) achieve partial remission; a ceiling of ~15-40% at 6 months also exists with biologic therapies, including tumor necrosis factor (TNF) inhibitors and secukinumab 7,8 (Table 1 [9][10][11][12][13][14][15][16][17][18][19][20] ). Treating patients with short symptom duration may increase the proportion of patients reaching clinical remission to ~50% 9,21,22 .…”